Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Palisade Bio (Nasdaq: PALI), a biopharmaceutical company focusing on autoimmune, inflammatory, and fibrotic diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee approved an option grant for 5,000 shares of common stock to Joerg Heyer, the new Head of Translational Science and Medicine, as a material inducement to employment.
The option, issued on August 16, 2024, has an exercise price of $3.94, matching the closing price of Palisade's common stock on the grant date. The option will vest quarterly over three years, contingent on Mr. Heyer's continued service to the company.
Palisade Bio (Nasdaq: PALI), una compagnia biofarmaceutica focalizzata su malattie autoimmuni, infiammatorie e fibrotiche, ha annunciato un'indennità di incentivo secondo la Regola di quotazione Nasdaq 5635(c)(4). Il Comitato per la Compensazione dell'azienda ha approvato un'assegnazione di opzioni per 5.000 azioni di azioni ordinarie a Joerg Heyer, il nuovo Responsabile della Scienza Traslazionale e della Medicina, come incentivo significativo per l'assunzione.
L'opzione, emessa il 16 agosto 2024, ha un prezzo di esercizio di $3.94, corrispondente al prezzo di chiusura delle azioni ordinarie di Palisade nella data di assegnazione. L'opzione maturerà trimestralmente per tre anni, a condizione del continuo servizio del signor Heyer presso l'azienda.
Palisade Bio (Nasdaq: PALI), una empresa biofarmacéutica enfocada en enfermedades autoinmunes, inflamatorias y fibróticas, ha anunciado una concesión de incentivos bajo la Regla de Cotización de Nasdaq 5635(c)(4). El Comité de Compensación de la empresa aprobó una concesión de opciones por 5,000 acciones de acciones comunes a Joerg Heyer, el nuevo Jefe de Ciencia Traslacional y Medicina, como un incentivo material para el empleo.
La opción, emitida el 16 de agosto de 2024, tiene un precio de ejercicio de $3.94, equivalente al precio de cierre de las acciones comunes de Palisade en la fecha de concesión. La opción se consolidará trimestralmente durante tres años, condicionado al continuo servicio del Sr. Heyer a la empresa.
Palisade Bio (Nasdaq: PALI)는 자가면역, 염증 및 섬유증 질환에 집중하는 생명공학 회사로서, Nasdaq 상장 규칙 5635(c)(4)에 따라 유인 보조금 발표를 하였습니다. 회사의 보상 위원회는 5,000주의 일반 주식에 대한 옵션을 Joerg Heyer 신임 번역 과학 및 의학 책임자에게 부여하였습니다. 이는 고용을 위한 중요한 유인책으로 설정되었습니다.
이번 옵션은 2024년 8월 16일에 발행되었으며, 행사 가격은 $3.94로, 보조금 날짜에 Palisade의 일반 주식 종가와 일치합니다. 이 옵션은 3년 동안 분기별로 발생할 예정이며, Mr. Heyer의 지속적인 회사 근무에 따라 달라집니다.
Palisade Bio (Nasdaq: PALI), une entreprise biopharmaceutique axée sur les maladies auto-immunes, inflammatoires et fibreuses, a annoncé une subvention incitative en vertu de la règle de cotation Nasdaq 5635(c)(4). Le comité de rémunération de l'entreprise a approuvé une attribution d'options de 5 000 actions ordinaires à Joerg Heyer, le nouveau responsable de la science translationnelle et de la médecine, comme incitation substantielle à l'emploi.
L'option, émise le 16 août 2024, a un prix d'exercice de 3,94 $, correspondant au prix de clôture des actions ordinaires de Palisade à la date d'attribution. L'option sera acquise par trimestres sur trois ans, conditionnée au service continu de M. Heyer au sein de l'entreprise.
Palisade Bio (Nasdaq: PALI), ein biopharmazeutisches Unternehmen, das sich auf autoimmune, entzündliche und fibrotische Erkrankungen konzentriert, hat einen Anreizzuschuss gemäß der Nasdaq-Listing-Regel 5635(c)(4) angekündigt. Der Vergütungsausschuss des Unternehmens genehmigte eine Optionsgewährung von 5.000 Aktien der Stammaktien an Joerg Heyer, den neuen Leiter der Translationalen Wissenschaft und Medizin, als wesentlichen Anreiz für die Anstellung.
Die Option, die am 16. August 2024 ausgegeben wurde, hat einen Ausübungspreis von $3.94, was dem Schlusskurs der Stammaktien von Palisade am Zuteilungsdatum entspricht. Die Option wird über einen Zeitraum von drei Jahren vierteljährlich ausübbar sein, abhängig von der fortgesetzten Tätigkeit von Herrn Heyer im Unternehmen.
- Appointment of new Head of Translational Science and Medicine, potentially strengthening the company's research capabilities
- Alignment of employee interests with shareholders through stock option grant
- Potential dilution of existing shareholders due to new stock option issuance
Carlsbad, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended.
The Company’s Compensation Committee approved the issuance of an option to purchase 5,000 shares of the Company’s common stock to Joerg Heyer, the new Head of Translational Science and Medicine, as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The option was issued on August 16, 2024, and has an exercise price of
About Palisade Bio
Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
PALI@jtcir.com
FAQ
What inducement grant did Palisade Bio (PALI) announce on August 19, 2024?
What is the exercise price and vesting schedule for the stock option granted by Palisade Bio (PALI)?
When was the inducement grant option issued by Palisade Bio (PALI)?
Who is the recipient of the inducement grant announced by Palisade Bio (PALI)?
